A commercial-stage med-tech firm which is devoted to design, develop, as well as market products which enhance the quality of life for patients who are suffering from psychiatric disorders, Neuronetics, Inc., made an announcement today that at the 2019 Military Health System Research Symposium, the researchers at the Uniformed Services University of the Health Sciences will be presenting the clinical data from 19th August till 22nd August from an investigator-initiated trial utilizing the firm’s NeuroStar Advanced Therapy TMS research system for traumatic brain injury and PTSD. Other than this, they will also be presenting a case report of a patient treated, as well as, studied for Alzheimer’s disease. NeuroStar system which is available in markets is approved by the Food and Drug Administration in the United States to treat Major Depressive Disorder in adult patients who are unable to receive satisfactory improvement from previous antidepressant medication in the existing episode.
The Chief Executive Officer, as well as, president of Neuronetics, Chris Thatcher stated that the investigators at Uniformed Services University employing the NeuroStar system for conducting possibly life-changing research genuinely share our passion, as well as, commitment for transforming lives. We are very well aware that challenges of mental health continue to make millions suffer, inclusive of those in the armed forces, and this type of research is essential when it comes to making steps towards novel treatment efforts for serving those who have dedicated their lives in an attempt to serve others.
The research is led by Managing Director and Chair of Rehabilitation Medicine Service at Walter Reed National Military Medical Center, Paul F. Pasquina, along with his colleague Mister Jared Garland. The research will be presented by Mister Garland in two poster sessions at the symposium stressing their NeuroStar system research, as well as, potential implications of the ground-breaking technology.